Robotic surgery is primed for an acceleration in activity – both in its clinical utilization as well as its strategic importance to the venture community and consolidators alike.
Given the significant opportunity to grow the overall market, the next wave of exciting robotic surgery innovations has caught the eye of medtech investors.
Read MoreThe clinical pipeline for cell therapies has grown significantly, with growth in allogeneic therapies outpacing autologous approaches. While the late-stage cell therapy pipeline is relatively thin, the FDA predicts by 2025 they will approve 10 to 20 cell and gene therapy products annually. In a new article Back Bay considers the recent surge in VC investments and opportunities for advancement.
Read MoreBack Bay Named a Top Consulting Firm in the Country
Read MoreBack Bay Life Science Advisors is ranked a Top Boutique Consulting Company and Top 50 in the US by Vault.
Read More2022 was the year of US-Nordic Collaboration for Back Bay Life Science Advisors
Read More